# Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants

> **NCT02510560** · PHASE3 · TERMINATED · sponsor: **Elgan Pharma Ltd.** · enrollment: 300 (actual)

## Conditions studied

- Premature Birth of Newborn
- Intestinal Malabsorption

## Interventions

- **DRUG:** NTRA-2112
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02510560
- **Lead sponsor:** Elgan Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-10-09
- **Primary completion:** 2018-04-25
- **Final completion:** 2018-04-25
- **Target enrollment:** 300 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02510560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02510560, "Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02510560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*